SC Slams Pharma Firm Over Cough Syrup Deaths
A five-judge Constitution Bench of the Supreme Court on Tuesday sharply criticised a domestic pharmaceutical company over deaths linked to its cough syrup that were reported in Uzbekistan, saying its conduct appeared deeply irresponsible and dangerous. The court’s comments came during hearings on a petition seeking accountability and regulatory action following the fatalities.
Supreme Court Rebukes Pharma Firm Over Cough Syrup Deaths
The Supreme Court said the actions of the Indian pharmaceutical company appeared “irrelevant, irresponsible and highly dangerous” in relation to deaths that occurred in Uzbekistan after the consumption of its cough syrup. The bench, led by the Chief Justice of India, expressed serious concern at the continued export and distribution of products once associated with adverse outcomes. The court underscored that manufacturers must ensure safety standards and quality compliance for all markets, domestic and international.
During proceedings, justices questioned the firm’s regulatory compliance and record-keeping, and noted the tragic human cost linked to the product.
Cough Syrup Deaths Reported In Uzbekistan
Authorities in Uzbekistan reported multiple fatalities among children and adults after ingestion of the cough syrup manufactured by the Indian firm. Preliminary investigations by Uzbek health regulators indicated potential contamination or toxic substances in the batches consumed, prompting the country to ban or recall the product. The incidents triggered public outcry and raised concerns over oversight of pharmaceutical exports.
The deaths have renewed scrutiny on protocols for testing, quality assurance and export certification of medicines produced in India.
Call For Accountability And Regulatory Reform
The Supreme Court emphasised that the pharmaceutical company must be held accountable for any lapses that contributed to the tragedy. The bench indicated that regulatory authorities need to strengthen surveillance, compliance enforcement and global reporting mechanisms to prevent recurrence. Lawyers appearing in the case sought directives for compensation and remedial action for affected families.
The matter is expected to continue before the court, with further hearings on evidence and compliance obligations.
